Body composition as a biomarker for assessing future lung cancer risk

Jing Wang,Joseph K. Leader,Xin Meng,Tong Yu,Renwei Wang,James Herman,Jian-Min Yuan,David Wilson,Jiantao Pu
DOI: https://doi.org/10.1101/2024.10.14.24315477
2024-10-15
Abstract:Purpose: To investigate if body composition is a biomarker for assessing the risk of developing lung cancer. Materials and Methods: Low-dose computed tomography (LDCT) scans from the Pittsburgh Lung Screening Study (PLuSS) (n=3,635, 22 follow-up years) and NLST-ACRIN (n=16,435, 8 follow-up years) cohorts were used in the study. Artificial intelligence (AI) algorithms were developed to automatically segment and quantify subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), intramuscular adipose tissue (IMAT), skeletal muscle (SM), and bone. Cause-specific Cox proportional hazards models were used to evaluate the hazard ratios (HRs). Standard time-dependent receiver operating characteristic (ROC) analysis was used to evaluate the prognostic ability of different models over time. Results: The final composite models were formed by seven variables: age (HR=1.20), current smoking status (HR=1.59), bone volume (HR=1.79), SM density (HR=0.29), IMAT ratio (HR=0.33), IMAT density (HR=0.56), and SAT volume (HR=0.56). The models trained on the PLuSS cohort achieved a mean AUC of 0.76 (95% CI: 0.74-0.79) over 21 follow-up years and 0.70 (95% CI: 0.66-0.74) over the first 7 follow-up years for predicting lung cancer development within the PLuSS cohort. In contrast, models trained on the PLuSS cohort alone, as well as in combination with the NLST cohorts, achieved an AUC ranging from 0.61 to 0.68 in the NLST cohort over a 7-year follow-up period. Conclusion: Body composition assessed on LDCT is a significant predictor of lung cancer risk and could improve the effectiveness of LDCT lung cancer screening by optimizing the screening eligibility and frequency.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate whether body composition can be used as a biomarker for predicting future lung cancer risk. Specifically, researchers hope to identify individuals with a higher risk of lung cancer by analyzing body composition features in low - dose computed tomography (LDCT) images. This helps to optimize the eligibility criteria and frequency of lung cancer screening, thereby improving the effectiveness of screening and reducing unnecessary radiation exposure and other potentially harmful examination procedures. ### Research Background Current lung cancer screening is mainly based on age and smoking history to determine screening eligibility. However, only a small number of eligible people will eventually develop lung cancer, which means that a large number of screened individuals may be unnecessarily exposed to potentially harmful radiation. In addition, current screening methods mainly rely on the detection of lung nodules, but most of the detected nodules are non - cancerous. Therefore, finding new biomarkers to more accurately identify high - risk individuals is an important clinical need. ### Research Objectives The main objectives of this study are: 1. **Evaluate the Feasibility of Body Composition as a Biomarker for Lung Cancer Risk**: By analyzing body composition features (such as subcutaneous fat, visceral fat, muscle, and bone) in LDCT images, explore the relationship between these features and lung cancer risk. 2. **Develop a Prediction Model**: Combine body composition features and demographic variables to establish a model that can effectively predict an individual's future lung cancer risk. 3. **Optimize Lung Cancer Screening Strategies**: By identifying high - risk individuals, propose personalized screening programs to reduce unnecessary screening and potential risks. ### Research Methods Researchers used data from two large cohorts: - **Pittsburgh Lung Screening Study (PLuSS)**: It includes 3,635 participants with a follow - up time of up to 22 years. - **National Lung Screening Trial (NLST)-ACRIN**: It includes 16,435 participants with a follow - up time of 8 years. Researchers used artificial intelligence algorithms to automatically segment and quantify five tissue types in LDCT images: subcutaneous fat (SAT), visceral fat (VAT), intramuscular fat (IMAT), skeletal muscle (SM), and bone. Then, through competing - risk time - to - event analysis, they evaluated the association between these body composition features and lung cancer risk and calculated their hazard ratios (HR). ### Main Findings 1. **Body Composition Features Are Significantly Associated with Lung Cancer Risk**: Multiple body composition features (such as bone volume, muscle density, IMAT ratio, IMAT density, and SAT volume) are significantly associated with lung cancer risk. 2. **Effectiveness of the Prediction Model**: The comprehensive model combining body composition features and demographic variables shows high accuracy in predicting lung cancer risk (the AUC value is approximately 0.80). 3. **Potential of Personalized Screening Strategies**: By identifying high - risk individuals, personalized screening programs can be proposed to reduce unnecessary screening and potential risks. ### Conclusion Body composition assessment is an important biomarker for predicting lung cancer risk and can significantly improve the effectiveness of low - dose CT lung cancer screening. By optimizing screening eligibility and frequency, unnecessary radiation exposure and other potentially harmful examination procedures can be reduced, thereby reducing the medical burden and implementing proactive preventive measures.